JP2015520184A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520184A5
JP2015520184A5 JP2015515646A JP2015515646A JP2015520184A5 JP 2015520184 A5 JP2015520184 A5 JP 2015520184A5 JP 2015515646 A JP2015515646 A JP 2015515646A JP 2015515646 A JP2015515646 A JP 2015515646A JP 2015520184 A5 JP2015520184 A5 JP 2015520184A5
Authority
JP
Japan
Prior art keywords
oxm
mal
lys
fms
fmoc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015515646A
Other languages
English (en)
Japanese (ja)
Other versions
JP6290193B2 (ja
JP2015520184A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2013/050481 external-priority patent/WO2013183052A1/en
Publication of JP2015520184A publication Critical patent/JP2015520184A/ja
Publication of JP2015520184A5 publication Critical patent/JP2015520184A5/ja
Application granted granted Critical
Publication of JP6290193B2 publication Critical patent/JP6290193B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015515646A 2012-06-04 2013-06-04 ペグ化oxm変異体 Active JP6290193B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655367P 2012-06-04 2012-06-04
US61/655,367 2012-06-04
PCT/IL2013/050481 WO2013183052A1 (en) 2012-06-04 2013-06-04 Pegylated oxm variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018020172A Division JP6549741B2 (ja) 2012-06-04 2018-02-07 ペグ化oxm変異体

Publications (3)

Publication Number Publication Date
JP2015520184A JP2015520184A (ja) 2015-07-16
JP2015520184A5 true JP2015520184A5 (enExample) 2016-07-21
JP6290193B2 JP6290193B2 (ja) 2018-03-07

Family

ID=49711501

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015515646A Active JP6290193B2 (ja) 2012-06-04 2013-06-04 ペグ化oxm変異体
JP2018020172A Active JP6549741B2 (ja) 2012-06-04 2018-02-07 ペグ化oxm変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018020172A Active JP6549741B2 (ja) 2012-06-04 2018-02-07 ペグ化oxm変異体

Country Status (17)

Country Link
US (3) US10537646B2 (enExample)
EP (1) EP2854838B1 (enExample)
JP (2) JP6290193B2 (enExample)
KR (1) KR102092025B1 (enExample)
CN (2) CN104684576B (enExample)
AU (2) AU2013273135B2 (enExample)
CA (1) CA2875599C (enExample)
CL (1) CL2014003307A1 (enExample)
CO (1) CO7160097A2 (enExample)
EA (1) EA201492269A1 (enExample)
HK (1) HK1209045A1 (enExample)
IL (1) IL236034B (enExample)
IN (1) IN2015DN00003A (enExample)
MX (1) MX362432B (enExample)
PE (1) PE20150181A1 (enExample)
SG (2) SG11201408054RA (enExample)
WO (1) WO2013183052A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
JP6290193B2 (ja) 2012-06-04 2018-03-07 オプコ バイオロジクス リミテッド ペグ化oxm変異体
KR102341581B1 (ko) 2012-11-20 2021-12-21 옵코 바이오로직스 리미티드 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
HRP20230405T8 (hr) 2014-12-10 2023-09-29 Opko Biologics Ltd. Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
CN107847546A (zh) * 2015-05-29 2018-03-27 Opko生物科学有限公司 聚乙二醇化的胃泌酸调节素变体
KR102172937B1 (ko) 2015-06-19 2020-11-03 옵코 바이오로직스 리미티드 장기-작용성 응고 인자 및 그의 제조 방법
WO2017075583A2 (en) * 2015-10-30 2017-05-04 The Research Foundation For The State University Of New York Oxyntomodulin analogs and methods of making and using same
CN113456820B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
WO2017212494A1 (en) * 2016-06-09 2017-12-14 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
BR112019000610A2 (pt) 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
CN108299554B (zh) * 2017-01-13 2021-05-25 博瑞生物医药(苏州)股份有限公司 胃泌酸调节素类似物
CN116854804A (zh) * 2017-08-16 2023-10-10 东亚St株式会社 酰化胃泌酸调节素肽类似物
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
WO2020165900A1 (en) 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
WO2025184364A1 (en) * 2024-03-01 2025-09-04 University Of Notre Dame Du Lac Self-assembling depots of adjuvant peptide therapies

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE68917883T2 (de) 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JP3148298B2 (ja) 1991-09-02 2001-03-19 帝人株式会社 軽量複合成形物の製造法
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
WO1996014336A1 (en) 1994-11-07 1996-05-17 Kyowa Hakko Kogyo Co., Ltd. Novel oxyntomodulin
WO1997006202A1 (en) 1995-08-10 1997-02-20 Kazunori Kataoka Block polymer having functional groups at both ends
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
AU760381B2 (en) 1998-04-28 2003-05-15 Laboratoires Serono Sa PEG-LHRH analog conjugates
US6617276B1 (en) 2000-07-21 2003-09-09 Johnson Matthey Public Limited Company Hydrocarbon trap/catalyst for reducing cold-start emissions from internal combustion engines
IL139400A0 (en) 2000-11-01 2001-11-25 Yeda Res & Dev Long-acting cytokine derivatives and pharmaceutical compositions comprising them
EP2123293A3 (en) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
KR100870013B1 (ko) 2002-08-27 2008-11-21 삼성전자주식회사 박막 트랜지스터 어레이 기판 및 그 제조 방법
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
AU2006258841B2 (en) * 2005-06-13 2012-05-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
EP2471811B1 (en) * 2006-02-22 2015-09-16 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
TWM345876U (en) 2008-06-17 2008-12-01 Yong-Xuan Ji Auxiliary device for mobile engine
AU2009292643B2 (en) * 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
PT2408800T (pt) 2009-03-20 2016-08-23 Hanmi Science Co Ltd Método para preparar um conjugado específico de local de um polipéptido fisiologicamente ativo
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
WO2012101619A1 (en) 2011-01-24 2012-08-02 Ben Gurion University Of The Negev Research And Development Authority A method for evaluating a mental disorder
JP6182134B2 (ja) 2011-06-02 2017-08-16 オプコ バイオロジクス リミテッド 長時間作用型glp−1/グルカゴン受容体アゴニスト
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
TR201901402T4 (tr) 2011-06-17 2019-02-21 Hanmi Science Co Ltd Oksintomodulin ve bir immünoglobulin fragmanı içeren bir konjugat ve onun kullanımı.
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
JP6290193B2 (ja) 2012-06-04 2018-03-07 オプコ バイオロジクス リミテッド ペグ化oxm変異体

Similar Documents

Publication Publication Date Title
JP2015520184A5 (enExample)
JP2015110654A5 (enExample)
JP2011522839A5 (enExample)
JP2015536943A5 (enExample)
JP2011511076A5 (enExample)
JP2016513638A5 (enExample)
JP2014521684A5 (enExample)
JP2008195730A5 (enExample)
CN111819217A (zh) 一种两亲性嵌段共聚物及其制备方法和纳米胶束载药系统
JP2018518537A5 (enExample)
JP2014129395A5 (enExample)
JP2014515013A5 (enExample)
JP2013520405A5 (enExample)
JP2008533007A5 (enExample)
JP2011500814A5 (enExample)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
JP2009017881A5 (enExample)
JP2008508859A5 (enExample)
JP2014514365A5 (enExample)
JP2016509011A5 (enExample)
JP2014533241A5 (enExample)
JP2019531293A5 (enExample)
JP2013510169A5 (enExample)
JP2019513752A5 (enExample)
RU2013120135A (ru) Глюкозозависимые инсулинотропные пептидные аналоги